



Personalized Medicine for Rheumatic Disorders

Guest Editor:

Dr. Ananta Paine

School of Medicine and Dentistry,
University of Rochester Medical
Center, 601 Elmwood Ave, Box
695, Rochester, NY 14642, USA

Deadline for manuscript
submissions:

closed (15 September 2022)

Message from the Guest Editor

Currently, rheumatic diseases are one of the most common causes of worldwide disability. In recent decades, significant technological advances have revolutionized the prognosis and outcome of many rheumatic diseases. Such advances include the concepts of tight control, treat-to-target, the development of biologics, and targeted therapies. However, the rheumatic disorders heterogeneities pose significant challenges to effectively selecting the most suitable treatment strategies among the available treatment options.

Genetics studies, along with the recently developed cutting-edge molecular techniques, advanced imaging modalities, and other novel approaches, are changing the landscape of autoimmune diseases from clinical and serological to biologic and molecular characterization. The ongoing and future molecular and clinical studies assisted by multi-omics approaches will enable us to select the optimal treatment for each patient based on clinical characteristics in the coming days.

The Special Issue invites reviews, articles, communications, and protocols about new findings on the epidemiology, pathogenesis, diagnosis, and treatment of rheumatic diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)